Jeremy Kortmansky, MD
The approval of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers (CRCs), according to a panel of experts in gastrointestinal (GI) malignancies.
Click to Enlarge
“Interestingly, if you take patients who had prior irinotecan, the 43% response rate really does not change, suggesting that prior irinotecan does not necessarily dampen the effect of the ADC payload, including the nature of how it’s delivered,” Corcoran said.
... to read the full story